McKesson Q3 EPS $9.34 Beats Estimates, Raises FY26 Guidance to $38.80–39.20
McKesson reported Q3 adjusted EPS of $9.34, beating estimates by $0.03 and rising 16.3% year over year on a $106.16 billion revenue, up 11.4% y/y. The company raised its full-year 2026 EPS guidance to $38.80–39.20 and now expects revenue growth of 12–16%.
1. Q3 Earnings and Revenue Beat
McKesson delivered adjusted Q3 EPS of $9.34, surpassing consensus by $0.03 and representing 16.3% year-over-year growth. Revenue rose 11.4% y/y to $106.16 billion, driven by higher prescription volumes and specialty product distribution.
2. Segment Performance Highlights
The Oncology & Multispecialty segment posted a 37% revenue increase to $13 billion, while North American Pharmaceutical grew 9% to $88.3 billion. Prescription Technology Solutions revenue climbed 9% to $1.5 billion; Medical-Surgical Solutions edged up 1% to $3 billion.
3. Guidance Upgrade and Strategic Outlook
McKesson raised full-year 2026 EPS guidance to $38.80–39.20 from $38.35–38.85 and lifted revenue growth targets to 12–16%. The company plans to spin off its Medical-Surgical Solutions business by H2 2027, completing its portfolio streamlining.